Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood

被引:4
|
作者
Meltzer, Eric B.
Barry, William T. [1 ]
Yang, Ivana V. [2 ]
Brown, Kevin K. [3 ]
Schwarz, Marvin I. [2 ]
Patel, Hamish [4 ]
Ashley, Allison
Noble, Paul W. [5 ]
Schwartz, David A. [2 ]
Steele, Mark P. [6 ]
机构
[1] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[2] Univ Colorado, Dept Med, Aurora, CO USA
[3] Natl Jewish Hlth, Denver, CO USA
[4] Edward Via Coll Osteopath Med, Spartanburg, SC USA
[5] Cedars Sinai, Dept Med, Los Angeles, CA USA
[6] Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care, Nashville, TN 37235 USA
来源
BMC GENOMICS | 2014年 / 15卷
基金
美国国家卫生研究院;
关键词
IPF; FIP; gene signature; Bayesian probit regression; INTERSTITIAL LUNG-DISEASE; PNEUMONIA; BIOPSIES;
D O I
10.1186/1471-2164-15-902
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Peripheral blood biomarkers might improve diagnostic accuracy for idiopathic pulmonary fibrosis (IPF). Results: Gene expression profiles were obtained from 89 patients with IPF and 26 normal controls. Samples were stratified according to severity of disease based on pulmonary function. The stratified dataset was split into subsets; two-thirds of the samples were selected to comprise the training set, while one-third was reserved for the validation set. Bayesian probit regression was used on the training set to develop a gene expression model for IPF versus normal. The gene expression model was tested by using it on the validation set to perform class prediction. Unsupervised clustering failed to discriminate between samples of different severity. Therefore, samples of all severities were included in the training and validation sets, in equal proportions. A gene signature model was developed from the training set. The model was built in an iterative fashion with the number of gene features selected to minimize the misclassification error in cross validation. The final model was based on the top 108 discriminating genes in the training set. The signature was successfully applied to the validation set, ROC area under the curve = 0.893, p < 0.0001. Using the optimal threshold (0.74) accurate class predictions were made for 77% of the test cases with sensitivity = 0.70, specificity = 1.00. Conclusions: By using Bayesian probit regression to develop a model, we show that it is entirely possible to make a diagnosis of IPF from the peripheral blood with gene signatures.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications
    Sherner, John
    Collen, Jacob
    King, Christopher S.
    Nathan, Steven D.
    CURRENT PULMONOLOGY REPORTS, 2012, 1 (04) : 233 - 242
  • [42] Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications
    John Sherner
    Jacob Collen
    Christopher S. King
    Steven D. Nathan
    Current Respiratory Care Reports, 2012, 1 (4): : 233 - 242
  • [43] The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis
    Lasky, Joseph A.
    Case, Amy
    Unterman, Avraham
    Kreuter, Michael
    Scholand, Mary Beth
    Chaudhary, Sachin
    Lofaro, Lori R.
    Johnson, Marla
    Huang, Jing
    Bhorade, Sangeeta M.
    Kennedy, Giulia C.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2022, 19 (06) : 916 - 924
  • [44] 2018 Clinical Practice Guideline Summary for Clinicians: Diagnosis of Idiopathic Pulmonary Fibrosis
    Thomson, Carey C.
    Duggal, Abhijit
    Bice, Thomas
    Lederer, David J.
    Wilson, Kevin C.
    Raghu, Ganesh
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2019, 16 (03) : 285 - 290
  • [45] The diagnostic role of cryobiopsy in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis
    Tomassetti, Sara
    Wells, Athol U.
    Costabel, Ulrich
    Alberto, Cavazza
    Colby, Thomas V.
    Giulio, Rossi
    Angelo, Carloni
    Nicola, Sverzellati
    Ryu, Jay H.
    Buccioli, Matteo
    Tantalocco, Paola
    Nanni, Oriana
    Carretta, Elisa
    Ravaglia, Claudia
    Gurioli, Christian
    Casoni, Gian Luca
    Gurioli, Carlo
    Romagnoli, Micaela
    Dubini, Alessandra
    Marco, Chilosi
    Poletti, Venerino
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [46] REVIEW OF IDIOPATHIC PULMONARY FIBROSIS DIAGNOSIS AND MANAGEMENT RECOMMENDATIONS IN EUROPE
    Xaubet, A.
    Behr, J.
    Bendstrup, E.
    Cottin, V.
    Hirani, N.
    Kaehler, C. M.
    Skold, C. M.
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2013, 30 (04) : 249 - 261
  • [47] Delays in idiopathic pulmonary fibrosis diagnosis and treatment: Time for change
    Jee, Adelle S.
    Chua, Felix
    RESPIROLOGY, 2022, 27 (01) : 10 - 11
  • [48] Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
    Patel, Harshank
    Shah, Jui Rakesh
    Patel, Divya Rakeshkumar
    Avanthika, Chaithanya
    Jhaveri, Sharan
    Gor, Kunj
    DM DISEASE-A-MONTH, 2023, 69 (07):
  • [49] Diagnosis of Idiopathic Pulmonary Fibrosis "Pragmatic Challenges in Clinical Practice"
    Tzilas, Vasilios
    Tzouvelekis, Argyris
    Chrysikos, Serafim
    Papiris, Spyridon
    Bouros, Demosthenes
    FRONTIERS IN MEDICINE, 2017, 4
  • [50] Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry
    Fahim, Ahmed
    Loughenbury, Maria
    Stewart, Iain
    Agnew, Sarah
    Almond, Howard
    Casimo, Leo
    Chaudhuri, Nazia
    Fletcher, Sophie, V
    Haney, Sarah
    Ho, Ling-Pei
    Hodkinson, Clare
    Minnis, Paul
    Palmer, Evelyn
    Wilson, Andrew M.
    British Thorac Soc
    BMJ OPEN RESPIRATORY RESEARCH, 2025, 12 (01)